Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $54.50.

A number of research firms have commented on SLP. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research note on Wednesday, July 3rd. JMP Securities initiated coverage on Simulations Plus in a research report on Tuesday, July 16th. They issued a “market perform” rating for the company. KeyCorp began coverage on Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. Finally, BTIG Research lowered their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total transaction of $792,600.00. Following the completion of the sale, the director now owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 60,750 shares of company stock valued at $2,145,055 in the last quarter. Company insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Simulations Plus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC raised its position in Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after acquiring an additional 1,100 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Simulations Plus in the 1st quarter valued at about $57,000. Allspring Global Investments Holdings LLC bought a new position in Simulations Plus during the first quarter worth about $70,000. Connecticut Wealth Management LLC acquired a new position in Simulations Plus during the first quarter worth approximately $204,000. Finally, Los Angeles Capital Management LLC bought a new stake in Simulations Plus in the second quarter valued at approximately $206,000. 78.08% of the stock is owned by institutional investors.

Simulations Plus Price Performance

Shares of Simulations Plus stock opened at $30.68 on Thursday. The firm has a fifty day moving average price of $33.08 and a two-hundred day moving average price of $40.56. Simulations Plus has a fifty-two week low of $29.37 and a fifty-two week high of $51.22. The company has a market cap of $613.91 million, a PE ratio of 63.92 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same quarter in the previous year, the company earned $0.18 earnings per share. The business’s revenue was up 19.9% compared to the same quarter last year. Analysts expect that Simulations Plus will post 0.54 earnings per share for the current fiscal year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.